Pediatric Nasal Decongestant Use – Evidence‑Based Recommendations

General Recommendations for Children < 6 Years

Avoid all over‑the‑counter (OTC) nasal and oral decongestants in children younger than 6 years because efficacy has not been demonstrated and safety concerns—including fatal outcomes—are documented. (Joint Task Force on Pediatric Decongestants) 1
Fatality data (1969‑2006): 54 deaths were linked to decongestants (pseudoephedrine, phenylephrine, ephedrine) in children ≤ 6 years; 43 of these occurred in infants < 1 year. (Surveillance data) 2
Serious adverse events reported at recommended doses include agitated psychosis, ataxia, hallucinations, tachyarrhythmias, and death. (Controlled safety reports) 1
Antihistamine‑decongestant combination products have been shown in controlled trials to be ineffective for relieving upper‑respiratory symptoms in young children. (Level I evidence) 2
FDA Nonprescription Drugs and Pediatric Advisory Committee (2007) recommendation: OTC cough‑and‑cold medicines should no longer be used in children < 6 years. (Regulatory guidance) 1

Extreme caution is required when using topical vasoconstrictors in infants because the therapeutic window is narrow and the risk of cardiovascular and central‑nervous‑system toxicity is high. (Pharmacologic safety review) 9

Pseudoephedrine is generally well tolerated in children over 6 years when dosed according to label recommendations. (Post‑marketing safety data) 1
Common side effects of pseudoephedrine in this age group include insomnia, hyperactivity, tachyarrhythmias, loss of appetite, and irritability. (Adverse‑event monitoring) 10
Drug‑interaction warning: Concomitant use of pseudoephedrine with stimulant medications (e.g., ADHD drugs) or caffeine should be avoided because it increases the risk of adverse cardiovascular and neuro‑behavioral events. (Pharmacovigilance guidance) 10
Phenylephrine—now the predominant OTC oral decongestant—has uncertain efficacy because it undergoes extensive gut metabolism, and robust clinical data supporting its decongestant effect are lacking. (Pharmacokinetic analysis) 10

Mechanism: Topical agents (oxymetazoline, xylometazoline, phenylephrine) produce nasal vasoconstriction and reduce mucosal edema. (Pharmacologic description) 10
Duration limit: Use should not exceed 3 days to prevent rhinitis medicamentosa (rebound congestion), which can appear as early as the third day of treatment. (Clinical practice guideline) 9
Indications for short‑term use include acute bacterial or viral upper‑respiratory infections, exacerbations of allergic rhinitis, and eustachian‑tube dysfunction. (Therapeutic recommendation) 9
Local adverse effects may consist of nasal stinging, burning, sneezing, and dryness. (Safety profile) 10

Medication errors and overdose are frequent sources of toxicity, often arising from the simultaneous use of multiple cold‑cough products, accidental ingestion, or intentional misuse. (Adverse‑event surveillance) 2
Blood‑pressure monitoring is advised for children receiving oral decongestants, especially those with pre‑existing cardiovascular disease, hyperthyroidism, closed‑angle glaucoma, or bladder‑neck obstruction. (Clinical safety recommendation) 10

Intranasal corticosteroids are the most effective therapy for allergic rhinitis in children and are safe when administered at approved pediatric doses. (Evidence‑based therapeutic hierarchy) 7
Second‑generation antihistamines (cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine) have excellent safety profiles and are well tolerated in young children. (Safety data from multiple trials) 1

The overall evidence base for pediatric decongestant use is limited; most safety information derives from adverse‑event reporting systems rather than large‑scale controlled trials. (Evidence‑level comment) 2
The 2008 Joint Task Force guidelines remain the most comprehensive source for pediatric decongestant recommendations, but they acknowledge substantial gaps in efficacy data for children < 6 years. (Guideline summary) 10